Jie Li, 52Baltimore, MD

6548499, Apr 15, 2003

Oct 20, 2000

09/622423

Kenneth G. Carson - Needham MA
David Thomas Connor - Ann Arbor MI
Jie Jack Li - Ann Arbor MI
Joseph Edwin Low - Brighton MI
Jay R. Luly - Wellesley MA
Steven Robert Miller - Ann Arbor MI
Bruce David Roth - Plymouth MI
Bharat Kalidas Trivedi - Farmington Hills MI

Millennium Pharmaceuticals, Inc. - Cambridge MA

A61K 31495

514249, 544353, 544356

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohns disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimers disease, graft versus host reaction, allograft rejections, or allergic diseases.

7860870, Dec 28, 2010

May 31, 2007

11/755972

Narayanan Sadagopan - Fremont CA, US
Jie Li - Stanford CA, US

Yahoo! Inc. - Sunnyvale CA

G06F 17/30

707748, 707758

The present invention provides for the detection of abnormal user behavior for a query session of an electronic search engine. A query session is initiated upon receipt of a user search request that includes one or more search terms. The search engine, in accordance with known search technology, generates a search results page that includes various hyperlinks, including for example web content hyperlinks, page navigation hyperlinks and advertising hyperlinks. Tracking user activities generates the clickstream associated with the search results page. The present invention determines a probability score for the clickstream and then this score is normalized. A comparison of the normalized probability score with other normalized probability scores for similar query sessions determines of the normalcy of the query session.

8170838, May 1, 2012

Apr 27, 2009

12/430805

Silvio J. Rabello - Palo Alto CA, US
William A. McGahan - Spicewood TX, US
Jie Li - Milpitas CA, US

Nanometrics Incorporated - Milpitas CA

H03F 1/26
G06F 15/00

702189, 359237, 372 24, 600409, 702 27, 702127

The process of modeling a complex two-dimensional periodic structure is improved by selectively truncating the Fourier expansion used in the calculation of resulting scatter signature from the model. The Fourier expansion is selectively truncated by determining the contribution for each harmonic order in the Fourier transform of the permittivity function and retaining the harmonic orders with a contribution that is above a threshold. The Fourier space may be compressed so that only the selected harmonic orders are used, thereby reducing the required memory and calculation times. The compressed Fourier space may be used in a real-time analysis of a sample or to generate a library that is used in the analysis of a sample.

8525993, Sep 3, 2013

Jan 29, 2010

12/696974

Silvio J. Rabello - Palo Alto CA, US
William A. McGahan - Spicewood TX, US
Jie Li - Milpitas CA, US
Yongdong Liu - Cupertino CA, US

Nanometrics Incorporated - Milpitas CA

G01J 4/00

356368, 356369

Asymmetry metrology is performed using at least a portion of Mueller matrix elements, including, e. g. , the off-diagonal elements of the Mueller matrix. The Mueller matrix may be generated using, e. g. , a spectroscopic or angle resolved ellipsometer that may include a rotating compensator. The Mueller matrix is analyzed by fitting at least a portion of the elements to Mueller matrix elements calculated using a rigorous electromagnetic model of the sample or by fitting the off-diagonal elements to a calibrated linear response. The use of the Mueller matrix elements in the asymmetry measurement permits, e. g. , overlay analysis using in-chip devices thereby avoiding the need for special off-chip targets.

8586030, Nov 19, 2013

Mar 8, 2013

13/791313

Niven Rajin Narain - Cambridge MA, US
Jie Li - Miami FL, US
Kathryn J. Russell - New York NY, US
Indushekhar Persaud - Homestead FL, US

University of Miami - Miami FL

A61K 38/43

424 941

Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

2009031, Dec 24, 2009

Feb 11, 2009

12/369659

Howard Sard - Arlington MA, US
Yiliang Zhang - Lowell MA, US
Jie Li - Baltimore MD, US
Louis Shuster - Brookline MA, US
Bryan Roth - Durham NC, US
Niels Jensen - Carrboro NC, US

A61K 31/404
C07D 209/14

514415, 548491

Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

2010004, Feb 25, 2010

Aug 21, 2009

12/545406

Guohan Yang - Mansfield MA, US
Ton T. Hai - Round Lake IL, US
Bennett Melnick - Chicago IL, US
Paul Sanders - Greendale WI, US
Cong Jiang - Gurnee IL, US
Catherine Quinn - Mundelein IL, US
Jie Li - Cary NC, US
Arounaguiry Ambroise - Cary NC, US
Larry R. Brown - Newton MA, US

BAXTER HEALTHCARE S.A. - Glattpark (Opfikon)
BAXTER INTERNATIONAL INC. - Deerfield IL

A61K 38/16
C07D 207/46
C08F 8/00
C08B 37/00
C07H 5/04
C08B 37/08
C08B 37/10
C08B 37/02
C07K 2/00
C07K 14/00
C07K 14/745
C07K 14/505
C07K 14/755
C12N 9/48
A61K 38/02
C07C 69/63
C07C 69/66
A61P 43/00

514 12, 548542, 525 55, 5361231, 536 187, 536102, 536103, 536 54, 536 21, 536 20, 536112, 530300, 530350, 530380, 530381, 530397, 530383, 435212, 514 2, 560226, 560186

The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.

2011014, Jun 16, 2011

Aug 10, 2010

12/853782

Amy Elder - Arlington MA, US
Geraldine Harriman - Charlestown RI, US
Silvana Leit - Kirkland, CA
Jie Li - Melrose MA, US
Howard Sard - Arlington MA, US
Yiliang Zhang - Stoneham MA, US
Doug Wilson - Ayer MA, US

A61K 31/553
C07D 209/14
C07D 401/12
C07D 409/12
C07D 409/10
C07D 405/10
C07D 401/10
C07D 409/06
C07D 401/06
C07D 413/06
C07D 403/06
A61K 31/4045
A61K 31/4439
A61K 31/5377
A61K 31/496
A61K 31/4184
A61P 3/10
A61P 25/22
A61P 25/24
A61P 25/00
A61P 25/18
A61P 3/04

51421115, 548504, 5462774, 548467, 548466, 544144, 548468, 540544, 514415, 514339, 514414, 5142352, 51425409, 514394

Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.